BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222
Phase 1
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT01653639
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
- Conditions
- Gastrointestinal Stromal Tumors
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Bayer
- Registration Number
- NCT01646593
A Swedish Questionnaire Study to Investigate the Perception of Menstrual Bleedings
Completed
- Conditions
- Menorrhagia
- Interventions
- Behavioral: No drug
- First Posted Date
- 2012-07-18
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1547
- Registration Number
- NCT01643304
Validation Study for Endometriosis PRO
Completed
- Conditions
- Endometriosis
- Interventions
- Other: No drug
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 275
- Registration Number
- NCT01643122
Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027)
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 955
- Registration Number
- NCT01638910
Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding
Phase 3
Completed
- Conditions
- Metrorrhagia
- Interventions
- Drug: EV/DNG (Qlaira, Natazia, BAY86-5027)Drug: placebo
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 339
- Registration Number
- NCT01638923
A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150
Phase 2
Completed
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- Drug: eptacog alfa [activated]Drug: BAY86-6150
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT01625390
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Completed
- Conditions
- Venous ThrombosisDeep Vein Thrombosis
- Interventions
- Drug: Rivaroxaban (Xarelto, BAY59-7939)Drug: Standard of care
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5145
- Registration Number
- NCT01619007
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 705
- Registration Number
- NCT01618370
Diabetes Treatment With Glucobay in Combination With Metformin
- First Posted Date
- 2012-06-06
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19509
- Registration Number
- NCT01612741
Β© Copyright 2025. All Rights Reserved by MedPath